Xevinapant is under clinical development by Ascenta Therapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase I drugs for Anaplastic Astrocytoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Xevinapant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Xevinapant overview
Xevinapant (Debio-1143) is under development for the treatment of high-grade glioma, recurrent glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic mixed glioma. It is formulated as a capsule and is administered through oral route. The drug candidate acts by targeting IAP repeat-containing protein 2 (CIAP1), IAP repeat-containing protein 3 (CIAP2), IAP repeat-containing protein 7 (livin) and IAP repeat-containing protein 4 ( XIAP). It is a new chemical entity. It was also under development for the treatment of pancreatic cancer, prostate cancer, bladder cancer, relapsed acute myelogenous leukemia (AML), advanced solid tumors, lymphomas, epithelial ovarian cancer and basal-like/claudin-low triple negative breast cancer, non-small cell lung cancer (NSCLC), small-cell lung cancer, esophageal cancer, epithelial ovarian cancer, primary peritoneal cancer, gastric cancer, colorectal cancer, endometrial cancer, cervical cancer, head and neck cancer squamous cell carcinoma, pancreatic ductal adenocarcinoma, oropharyngeal cancer, oral cavity (mouth) cancer, nasopharynx cancer, hypopharyngeal cancer and laryngeal cancer.
Ascenta Therapeutics overview
Ascenta Therapeutics (Ascenta) is a biopharmaceutical company that research, develops and manufactures drugs to treat cancer. Ascenta is headquartered in Malvern, Pennsylvania, the US.
For a complete picture of Xevinapant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
